BONAIRESSWISS AG aims, from Switzerland, the proper land for quality, transparency, and reliability, to reach the complementary therapies market, bringing to it the scientific resources, the quality of production, and the reliability of more than 80 years of experience of its leaders in the field of homeopathy.
Our company was constituted with the mission to produce, distribute, and commercialize the homeopathic products developed by the research.
Having thus, in its controlling a group of highly qualified professionals for the implantation and development of the company, its products, and brands within the Swiss and international market. The team merges knowledge related to research and development in the field of homeopathy, production, and marketing in the pharmaceutical area, and human resources management and business managing.
Highly diluted substances are intended to modulate immune system responses resulting in reduced frequency of various diseases, and present no risk of side-effects. It was developed and tested several highly diluted tinctures and it was described the biological activity of M1, M2, and M8.
BONAIRESWISS AG has partners around the world that sell products developed and patented by BONAIRESWISS AG locally. Partners who are responsible for quality in production and humanity and love in distribution and marketing.
“…Awesome, less than 24 hours later the macrophages were activated. Because of my studies with macrophage receptors, I was sure the medicine should have an actives principle inside. But even using 30% of medicine in culture, the macrophages were very well, and this was incredible also. I used to put µL of substances (LPS, IFN, and so on) in a culture medium….”
Prf. Dr. Dorly de Freitas Buchi
How to get in contact with BONAIRESWISS AG and our partners worldwide.
Modul8 South Africa
Natel Neutratec India
Pay attention to our blog and be aware of the news in BONAIRESWISS AG.
Therefore, in summary, M8 (ANBUTA PLUS) is a homeopathic complex medicine (HCM) with immunomodulatory properties, without toxicity nor mutagenic effects. This homeopathic immunotherapy can kindly restore the immune system to recognize tumor cells and can be used as therapeutic interventions in disorders where the immune system is compromised.
A new coronavirus, 2019-nCoV, related to the SARS and MERS diseases that have caused epidemics, has been discovered in China and started to spread. There are, until now, no vaccines or antiviral drugs that are approved for the prevention or treatment of the new virus.
A BONAIRESWISS A.G. is a company concerned with the quality and efficiency of its products. Ready to be tested, two of its products have been in the hands of scientists for over 20 years seeking, with their research results, to prove the efficiency and reliability of...
Get in contact with BONAIRESWISS AG. for more information.
BONAIRESSWISS AG aims, from Switzerland, the proper land for quality, transparency, and reliability, complementary therapies market, bringing to it the scientific resources, the quality of production and the reliability of more than 80 years of experience of its leaders in the field of homeopathy.
BONAIRESWISS A.G. is a company headquartered in Zürich on 5 March 2017. At the address, Nüschelerstrasse 31.
Our company was constituted with the mission to produce, distribute, and commercialize the homeopathic products developed by Dra. Dorly de Freitas Buchi, the main researcher at the Laboratory of Study of Neoplastic and Inflammatory Cells at Federal University of Paraná, Brazil.
Having thus, in its controlling a group of highly qualified professionals for the implantation and development of the company, its products, and brands within the Swiss and international market. The team merges knowledge related to research and development in the field of homeopathy, production, and marketing in the pharmaceutical area, and human resources management and business managing.